{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:45:15Z","timestamp":1786981515923,"version":"build-2736575974"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12017-0","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:32:21Z","timestamp":1779802341000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cancer immunotherapy: mechanisms, clinical applications, resistance and future directions"],"prefix":"10.1007","volume":"53","author":[{"given":"Aysima","family":"\u00d6nal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furkan","family":"Ayaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Aydemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"issue":"385","key":"12017_CR1","doi-asserted-by":"publisher","first-page":"eaak9679","DOI":"10.1126\/scitranslmed.aak9679","volume":"9","author":"E Allen","year":"2017","unstructured":"Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, Feyen K, Tawney J, Hanahan D, Michael IP, Bergers G (2017) Combined antiangiogenic and anti\u2013PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med 9(385):eaak9679. https:\/\/doi.org\/10.1126\/scitranslmed.aak9679","journal-title":"Sci Transl Med"},{"key":"12017_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40364-023-00540-2","volume":"11","author":"K Asleh","year":"2023","unstructured":"Asleh K, Dery V, Taylor C, Davey M, Djeungoue-Petga M-A, Ouellette RJ (2023) Extracellular vesicle-based liquid biopsy biomarkers and their application in precision immuno-oncology. Biomark Res 11:99. https:\/\/doi.org\/10.1186\/s40364-023-00540-2","journal-title":"Biomark Res"},{"issue":"8","key":"12017_CR3","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, McClanahan TK (2017) IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade. J Clin Investig 127(8):2930\u20132940. https:\/\/doi.org\/10.1172\/JCI91190","journal-title":"J Clin Investig"},{"key":"12017_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG (2021) Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance. Annu Rev Pathol 16:223\u2013249. https:\/\/doi.org\/10.1146\/annurev-pathol-042020-042741","journal-title":"Annu Rev Pathol"},{"key":"12017_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","volume":"18","author":"R Baghban","year":"2020","unstructured":"Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, Zare P (2020) Tumor microenvironment complexity and therapeutic implications at a glance. Cell Communication Signal 18:59. https:\/\/doi.org\/10.1186\/s12964-020-0530-4","journal-title":"Cell Communication Signal"},{"key":"12017_CR6","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41580-023-00615-w","volume":"24","author":"A Baysoy","year":"2023","unstructured":"Baysoy A, Bai Z, Satija R, Fan R (2023) The technological landscape and applications of single-cell multi-omics. Nat Rev Mol Cell Biol 24:695\u2013713. https:\/\/doi.org\/10.1038\/s41580-023-00615-w","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"12017_CR7","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G Bindea","year":"2013","unstructured":"Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Galon J (2013) Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39(4):782\u2013795. https:\/\/doi.org\/10.1016\/j.immuni.2013.10.003","journal-title":"Immunity"},{"issue":"5","key":"12017_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Krummel MF (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24(5):541\u2013550. https:\/\/doi.org\/10.1038\/s41591-018-0014-x","journal-title":"Nat Med"},{"issue":"8","key":"12017_CR9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Champiat S (2016) Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Reviews Clin Oncol 13(8):473\u2013486. https:\/\/doi.org\/10.1038\/nrclinonc.2016.58","journal-title":"Nat Reviews Clin Oncol"},{"issue":"4","key":"12017_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JOP.18.00005","volume":"14","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Thompson JA (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline summary. J Oncol Pract 14(4):247\u2013249. https:\/\/doi.org\/10.1200\/JOP.18.00005","journal-title":"J Oncol Pract"},{"issue":"1","key":"12017_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Desai A (2016) CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition. Am J Clin Oncol 39(1):98\u2013106. https:\/\/doi.org\/10.1097\/COC.0000000000000239","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"12017_CR12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","volume":"36","author":"ML Burr","year":"2019","unstructured":"Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, Dawson MA (2019) An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer. Cancer Cell 36(4):385\u2013401e8. https:\/\/doi.org\/10.1016\/j.ccell.2019.08.008","journal-title":"Cancer Cell"},{"issue":"6","key":"12017_CR13","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"C-H Chang","year":"2015","unstructured":"Chang C-H, Qiu J, O\u2019Sullivan D, Buck MD, Noguchi T, Curtis JD, Pearce EL (2015) Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162(6):1229\u20131241. https:\/\/doi.org\/10.1016\/j.cell.2015.08.016","journal-title":"Cell"},{"issue":"1","key":"12017_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I (2013) Oncology meets immunology: The cancer-immunity cycle. Immunity 39(1):1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012","journal-title":"Immunity"},{"issue":"7637","key":"12017_CR15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer\u2013immune set point. Nature 541(7637):321\u2013330. https:\/\/doi.org\/10.1038\/nature21349","journal-title":"Nature"},{"key":"12017_CR16","doi-asserted-by":"publisher","first-page":"779691","DOI":"10.3389\/fimmu.2022.779691","volume":"13","author":"A Chennamadhavuni","year":"2022","unstructured":"Chennamadhavuni A, Abushahin L, Jin N, Presley CJ, Manne A (2022) Risk factors and biomarkers for immune-related adverse events: A practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Front Immunol 13:779691. https:\/\/doi.org\/10.3389\/fimmu.2022.779691","journal-title":"Front Immunol"},{"issue":"2","key":"12017_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrc3670","volume":"14","author":"PG Coulie","year":"2014","unstructured":"Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T (2014) Tumour antigens recognized by T lymphocytes: At the core of cancer immunotherapy. Nat Rev Cancer 14(2):135\u2013146. https:\/\/doi.org\/10.1038\/nrc3670","journal-title":"Nat Rev Cancer"},{"issue":"6411","key":"12017_CR18","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Loboda A (2018) Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy. Science 362(6411):eaar3593. https:\/\/doi.org\/10.1126\/science.aar3593","journal-title":"Science"},{"key":"12017_CR19","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"S Das","year":"2019","unstructured":"Das S, Johnson DB (2019) Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer 7:306. https:\/\/doi.org\/10.1186\/s40425-019-0805-8","journal-title":"J Immunother Cancer"},{"issue":"6","key":"12017_CR20","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo DG, Ruffell B (2019) Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol 19(6):369\u2013382. https:\/\/doi.org\/10.1038\/s41577-019-0127-6","journal-title":"Nat Rev Immunol"},{"key":"12017_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","volume":"28","author":"L Derosa","year":"2021","unstructured":"Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, Zitvogel L (2021) Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat Med 28:315\u2013324. https:\/\/doi.org\/10.1038\/s41591-021-01655-5","journal-title":"Nat Med"},{"issue":"4","key":"12017_CR22","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41591-022-01694-6","volume":"28","author":"N Dizman","year":"2022","unstructured":"Dizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, Pal SK (2022) Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: A randomized phase 1 trial. Nat Med 28(4):704\u2013712. https:\/\/doi.org\/10.1038\/s41591-022-01694-6","journal-title":"Nat Med"},{"issue":"11","key":"12017_CR23","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 3(11):991\u2013998. https:\/\/doi.org\/10.1038\/ni1102-991","journal-title":"Nat Immunol"},{"key":"12017_CR24","doi-asserted-by":"publisher","first-page":"104907","DOI":"10.1016\/j.critrevonc.2025.104907","volume":"214","author":"M Ebrahimnezhad","year":"2025","unstructured":"Ebrahimnezhad M, Valizadeh A, Yousefi B (2025) Ferroptosis and immunotherapy: Breaking barriers in cancer treatment resistance. Crit Rev Oncol\/Hematol 214:104907. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104907","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"2","key":"12017_CR25","doi-asserted-by":"publisher","first-page":"e001369","DOI":"10.1136\/jitc-2020-001369","volume":"8","author":"I Efimova","year":"2020","unstructured":"Efimova I, Catanzaro E, Van der Meeren L, Turubanova VD, Hammad H, Mishchenko TA, Krysko DV (2020) Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. J Immunother Cancer 8(2):e001369. https:\/\/doi.org\/10.1136\/jitc-2020-001369","journal-title":"J Immunother Cancer"},{"issue":"20","key":"12017_CR26","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, Cheng A-L (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382(20):1894\u20131905. https:\/\/doi.org\/10.1056\/NEJMoa1915745","journal-title":"N Engl J Med"},{"issue":"4","key":"12017_CR27","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"22","author":"M Freeman-Keller","year":"2016","unstructured":"Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS (2016) Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22(4):886\u2013894. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1136","journal-title":"Clin Cancer Res"},{"issue":"12","key":"12017_CR28","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman WH, Zitvogel L, Saut\u00e8s-Fridman C, Kroemer G (2017) The immune contexture in cancer prognosis and treatment. Nat Reviews Clin Oncol 14(12):717\u2013734. https:\/\/doi.org\/10.1038\/nrclinonc.2017.101","journal-title":"Nat Reviews Clin Oncol"},{"issue":"1","key":"12017_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","volume":"5","author":"DI Gabrilovich","year":"2017","unstructured":"Gabrilovich DI (2017) Myeloid-derived suppressor cells. Cancer Immunol Res 5(1):3\u20138. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0297","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"12017_CR30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O, Zitvogel L, Kroemer G (2017) Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol 17(2):97\u2013111. https:\/\/doi.org\/10.1038\/nri.2016.107","journal-title":"Nat Rev Immunol"},{"issue":"22","key":"12017_CR31","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Garassino MC (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378(22):2078\u20132092. https:\/\/doi.org\/10.1056\/NEJMoa1801005","journal-title":"N Engl J Med"},{"key":"12017_CR32","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.coi.2016.01.007","volume":"39","author":"F Garrido","year":"2016","unstructured":"Garrido F, Aptsiauri N (2016) Impairment of antigen presentation in tumors: Mechanisms and implications for immunotherapy. Curr Opin Immunol 39:72\u201380. https:\/\/doi.org\/10.1016\/j.coi.2016.01.007","journal-title":"Curr Opin Immunol"},{"issue":"6371","key":"12017_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Wargo JA (2018) Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients. Science 359(6371):97\u2013103. https:\/\/doi.org\/10.1126\/science.aan4236","journal-title":"Science"},{"issue":"Suppl 4","key":"12017_CR34","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"JBAG Haanen","year":"2017","unstructured":"Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(Suppl 4):iv119\u2013iv142. https:\/\/doi.org\/10.1093\/annonc\/mdx225","journal-title":"Ann Oncol"},{"issue":"5","key":"12017_CR35","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5):646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"issue":"6","key":"12017_CR36","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","volume":"21","author":"KJ Hiam-Galvez","year":"2021","unstructured":"Hiam-Galvez KJ, Allen BM, Spitzer MH (2021) Systemic immunity in cancer. Nat Rev Cancer 21(6):345\u2013359. https:\/\/doi.org\/10.1038\/s41568-021-00347-z","journal-title":"Nat Rev Cancer"},{"issue":"7738","key":"12017_CR37","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","volume":"565","author":"N Hilf","year":"2019","unstructured":"Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanovi\u0107 S, Gouttefangeas C, Wick W (2019) Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565(7738):240\u2013245. https:\/\/doi.org\/10.1038\/s41586-018-0810-y","journal-title":"Nature"},{"issue":"18","key":"12017_CR38","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","volume":"79","author":"DC Hinshaw","year":"2019","unstructured":"Hinshaw DC, Shevde LA (2019) The tumor microenvironment innately modulates cancer progression. Cancer Res 79(18):4557\u20134566. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3962","journal-title":"Cancer Res"},{"issue":"8","key":"12017_CR39","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"issue":"6230","key":"12017_CR40","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348(6230):74\u201380. https:\/\/doi.org\/10.1126\/science.aaa6204","journal-title":"Science"},{"issue":"1","key":"12017_CR41","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.4110\/in.2023.23.e7","volume":"23","author":"H Kang","year":"2023","unstructured":"Kang H, Kim H, Kim H (2023) Short-chain fatty acids and host immunity in cancer. Immune Netw 23(1):e7. https:\/\/doi.org\/10.4110\/in.2023.23.e7","journal-title":"Immune Netw"},{"issue":"22","key":"12017_CR42","doi-asserted-by":"publisher","first-page":"6442","DOI":"10.1158\/0008-5472.CAN-17-2006","volume":"77","author":"JN Kather","year":"2017","unstructured":"Kather JN, Poleszczuk J, Suarez-Carmona M, Krisam J, Charoentong P, Valous NA, Halama N (2017) In silico modeling of immunotherapy and stroma-targeting therapies in human colorectal cancer. Cancer Res 77(22):6442\u20136452. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-2006","journal-title":"Cancer Res"},{"key":"12017_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer G, Galluzzi L, Kepp O, Zitvogel L (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31:51\u201372. https:\/\/doi.org\/10.1146\/annurev-immunol-032712-100008","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"12017_CR44","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Cowey CL, Lao CD, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"issue":"16","key":"12017_CR45","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, Wolchok JD (2019) Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381(16):1535\u20131546. https:\/\/doi.org\/10.1056\/NEJMoa1910836","journal-title":"N Engl J Med"},{"issue":"26","key":"12017_CR46","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Diaz LA Jr. (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509\u20132520. https:\/\/doi.org\/10.1056\/NEJMoa1500596","journal-title":"N Engl J Med"},{"issue":"9","key":"12017_CR47","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41568-020-0273-y","volume":"20","author":"RD Leone","year":"2020","unstructured":"Leone RD, Powell JD (2020) Metabolism of immune cells in cancer. Nat Rev Cancer 20(9):516\u2013531. https:\/\/doi.org\/10.1038\/s41568-020-0273-y","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"12017_CR48","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","volume":"184","author":"K Litchfield","year":"2021","unstructured":"Litchfield K, Reading JL, Puttick C, Thakkar K, Abbosh C, Bentham R, Swanton C (2021) Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184(3):596\u2013614e14. https:\/\/doi.org\/10.1016\/j.cell.2021.01.002","journal-title":"Cell"},{"key":"12017_CR49","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40364-021-00314-8","volume":"9","author":"X Liu","year":"2021","unstructured":"Liu X, Shi Y, Zhang D, Zhou Q, Liu J, Chen M, Wang M (2021) Risk factors for immune-related adverse events: What have we learned and what lies ahead? Biomark Res 9:79. https:\/\/doi.org\/10.1186\/s40364-021-00314-8","journal-title":"Biomark Res"},{"key":"12017_CR50","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41467-017-02630-w","volume":"9","author":"N Luo","year":"2018","unstructured":"Luo N, Nixon MJ, Gonzalez-Ericsson PI, Sanchez V, Opalenik SR, Li H, Balko JM (2018) DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun 9:248. https:\/\/doi.org\/10.1038\/s41467-017-02630-w","journal-title":"Nat Commun"},{"key":"12017_CR51","doi-asserted-by":"publisher","first-page":"14430","DOI":"10.1038\/s41598-021-93577-y","volume":"11","author":"M Luu","year":"2021","unstructured":"Luu M, Weigand K, Wedi F, Breidenbend C, Leister H, Pautz S, Visekruna A (2021) Regulation of the effector function of CD8\u2009+\u2009T cells by gut microbiota-derived metabolite butyrate. Sci Rep 11:14430. https:\/\/doi.org\/10.1038\/s41598-021-93577-y","journal-title":"Sci Rep"},{"issue":"5","key":"12017_CR52","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41423-026-01405-y","volume":"23","author":"H Luxenburger","year":"2026","unstructured":"Luxenburger H, Thimme R, Hofmann M (2026) T cell adaptation in chronic infections and tumors. Cell Mol Immunol 23(5):440\u2013456. https:\/\/doi.org\/10.1038\/s41423-026-01405-y","journal-title":"Cell Mol Immunol"},{"issue":"9","key":"12017_CR53","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Coukos G (2019) Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance. Nat Reviews Clin Oncol 16(9):563\u2013580. https:\/\/doi.org\/10.1038\/s41571-019-0218-0","journal-title":"Nat Reviews Clin Oncol"},{"issue":"6280","key":"12017_CR54","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJS, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Swanton C (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351(6280):1463\u20131469. https:\/\/doi.org\/10.1126\/science.aaf1490","journal-title":"Science"},{"key":"12017_CR55","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"J-M Michot","year":"2016","unstructured":"Michot J-M, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Soria J-C (2016) Immune-related adverse events with immune checkpoint blockade: A comprehensive review. Eur J Cancer 54:139\u2013148. https:\/\/doi.org\/10.1016\/j.ejca.2015.11.016","journal-title":"Eur J Cancer"},{"key":"12017_CR56","doi-asserted-by":"publisher","first-page":"886930","DOI":"10.3389\/fendo.2022.886930","volume":"13","author":"CA Muir","year":"2022","unstructured":"Muir CA, Tsang VHM, Menzies AM, Clifton-Bligh RJ (2022) Immune related adverse events of the thyroid - A narrative review. Front Endocrinol 13:886930. https:\/\/doi.org\/10.3389\/fendo.2022.886930","journal-title":"Front Endocrinol"},{"issue":"18","key":"12017_CR57","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1158\/0008-5472.CAN-11-1094","volume":"71","author":"MZ Noman","year":"2015","unstructured":"Noman MZ, Janji B, Kaminska B, Van Moer K, Pierson S, Przanowski P, Chouaib S (2015) Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. Cancer Res 71(18):5976\u20135986. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-1094","journal-title":"Cancer Res"},{"issue":"1","key":"12017_CR58","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy R, Pollard JW (2014) Tumor-associated macrophages: From mechanisms to therapy. Immunity 41(1):49\u201361. https:\/\/doi.org\/10.1016\/j.immuni.2014.06.010","journal-title":"Immunity"},{"issue":"7662","key":"12017_CR59","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Wu CJ (2017) An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547(7662):217\u2013221. https:\/\/doi.org\/10.1038\/nature22991","journal-title":"Nature"},{"issue":"4","key":"12017_CR60","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrc3258","volume":"12","author":"K Palucka","year":"2012","unstructured":"Palucka K, Banchereau J (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12(4):265\u2013277. https:\/\/doi.org\/10.1038\/nrc3258","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"12017_CR61","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Ciuleanu T-E, Cobo M, Schenker M, Zurawski B, Menezes J, Reck M (2021) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): An international, randomised, open-label, phase 3 trial. Lancet Oncol 22(2):198\u2013211. https:\/\/doi.org\/10.1016\/S1470-2045(20)30641-0","journal-title":"Lancet Oncol"},{"issue":"11","key":"12017_CR62","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.3390\/cancers17111854","volume":"17","author":"F P\u00e9rez-Dom\u00ednguez","year":"2025","unstructured":"P\u00e9rez-Dom\u00ednguez F, Quezada-Monr\u00e1s C, C\u00e1rcamo L, Mu\u00f1oz JP, Carrillo-Beltr\u00e1n D (2025) Oncolytic viruses as a novel therapeutic approach for colorectal cancer: Mechanisms, current advances, and future directions. Cancers 17(11):1854. https:\/\/doi.org\/10.3390\/cancers17111854","journal-title":"Cancers"},{"issue":"1","key":"12017_CR63","doi-asserted-by":"publisher","first-page":"2514040","DOI":"10.1080\/2162402X.2025.2514040","volume":"14","author":"K Pojar","year":"2025","unstructured":"Pojar K, Reckendorfer D, Strauss J, Szaffich S, Ahmadi-Erber S, Schippers T, Lauterbach H (2025) Combining local cytokine delivery and systemic immunization with recombinant artLCMV boosts antitumor efficacy in several preclinical tumor models. OncoImmunology 14(1):2514040. https:\/\/doi.org\/10.1080\/2162402X.2025.2514040","journal-title":"OncoImmunology"},{"issue":"2","key":"12017_CR64","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"12017_CR65","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon III, Dadu C, Ernstoff R, M. S (2017) Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer Toxicity Management Working Group. J Immunother Cancer 5:95. https:\/\/doi.org\/10.1186\/s40425-017-0300-z","journal-title":"J Immunother Cancer"},{"issue":"19","key":"12017_CR66","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, Brahmer JR (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823\u20131833. https:\/\/doi.org\/10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"issue":"6382","key":"12017_CR67","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359(6382):1350\u20131355. https:\/\/doi.org\/10.1126\/science.aar4060","journal-title":"Science"},{"issue":"6230","key":"12017_CR68","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Chan TA (2015) Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230):124\u2013128. https:\/\/doi.org\/10.1126\/science.aaa1348","journal-title":"Science"},{"issue":"6371","key":"12017_CR69","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill\u00e8re R, Zitvogel L (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359(6371):91\u201397. https:\/\/doi.org\/10.1126\/science.aan3706","journal-title":"Science"},{"issue":"6382","key":"12017_CR70","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.aar7112","volume":"359","author":"U Sahin","year":"2018","unstructured":"Sahin U, T\u00fcreci \u00d6 (2018) Personalized vaccines for cancer immunotherapy. Science 359(6382):1355\u20131360. https:\/\/doi.org\/10.1126\/science.aar7112","journal-title":"Science"},{"key":"12017_CR71","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","volume":"38","author":"S Sakaguchi","year":"2020","unstructured":"Sakaguchi S, Mikami N, Wing JB, Tanaka A, Ichiyama K, Ohkura N (2020) Regulatory T cells and human disease. Annu Rev Immunol 38:541\u2013566. https:\/\/doi.org\/10.1146\/annurev-immunol-042718-041717","journal-title":"Annu Rev Immunol"},{"issue":"6024","key":"12017_CR72","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: Integrating immunity\u2019s roles in cancer suppression and promotion. Science 331(6024):1565\u20131570. https:\/\/doi.org\/10.1126\/science.1203486","journal-title":"Science"},{"issue":"6230","key":"12017_CR73","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348(6230):69\u201374. https:\/\/doi.org\/10.1126\/science.aaa4971","journal-title":"Science"},{"issue":"6230","key":"12017_CR74","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP (2015) The future of immune checkpoint therapy. Science 348(6230):56\u201361. https:\/\/doi.org\/10.1126\/science.aaa8172","journal-title":"Science"},{"issue":"4","key":"12017_CR75","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168(4):707\u2013723. https:\/\/doi.org\/10.1016\/j.cell.2017.01.017","journal-title":"Cell"},{"issue":"9","key":"12017_CR76","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","volume":"5","author":"A Simonaggio","year":"2019","unstructured":"Simonaggio A, Michot J-M, Voisin A-L, Le Pavec J, Collins M, Lallart A, Marabelle A (2019) Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol 5(9):1310\u20131317. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1022","journal-title":"JAMA Oncol"},{"issue":"23","key":"12017_CR77","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Chan TA (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371(23):2189\u20132199. https:\/\/doi.org\/10.1056\/NEJMoa1406498","journal-title":"N Engl J Med"},{"issue":"51","key":"12017_CR78","doi-asserted-by":"publisher","first-page":"E10981","DOI":"10.1073\/pnas.1712514114","volume":"114","author":"ML Stone","year":"2017","unstructured":"Stone ML, Chiappinelli KB, Li H, Murphy LM, Travers ME, Topper MJ, Zahnow CA (2017) Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proc Natl Acad Sci USA 114(51):E10981\u2013E10990. https:\/\/doi.org\/10.1073\/pnas.1712514114","journal-title":"Proc Natl Acad Sci USA"},{"issue":"127","key":"12017_CR79","doi-asserted-by":"publisher","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","volume":"4","author":"JM Taube","year":"2012","unstructured":"Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen L (2012) Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4(127):127ra37. https:\/\/doi.org\/10.1126\/scitranslmed.3003689","journal-title":"Sci Transl Med"},{"issue":"26","key":"12017_CR80","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443\u20132454. https:\/\/doi.org\/10.1056\/NEJMoa1200690","journal-title":"N Engl J Med"},{"issue":"5","key":"12017_CR81","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian SL, Taube JM, Anders RA, Pardoll DM (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16(5):275\u2013287. https:\/\/doi.org\/10.1038\/nrc.2016.36","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"12017_CR82","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41591-018-0300-7","volume":"25","author":"EJ Topol","year":"2019","unstructured":"Topol EJ (2019) High-performance medicine: The convergence of human and artificial intelligence. Nat Med 25(1):44\u201356. https:\/\/doi.org\/10.1038\/s41591-018-0300-7","journal-title":"Nat Med"},{"key":"12017_CR83","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","volume":"10","author":"M Tufail","year":"2025","unstructured":"Tufail M, Jiang C-H, Li N (2025) Immune evasion in cancer: Mechanisms and cutting-edge therapeutic approaches. Signal Transduct Target Therapy 10:227. https:\/\/doi.org\/10.1038\/s41392-025-02280-1","journal-title":"Signal Transduct Target Therapy"},{"issue":"7528","key":"12017_CR84","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, Ribas A (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568\u2013571. https:\/\/doi.org\/10.1038\/nature13954","journal-title":"Nature"},{"key":"12017_CR85","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/978-3-319-91287-5_27","volume":"1072","author":"P Vaupel","year":"2018","unstructured":"Vaupel P, Multhoff G (2018) Hypoxia-\/HIF-1\u03b1-driven factors of the tumor microenvironment impeding antitumor immune responses and promoting malignant progression. Adv Exp Med Biol 1072:171\u2013175. https:\/\/doi.org\/10.1007\/978-3-319-91287-5_27","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"12017_CR86","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","volume":"19","author":"F Veglia","year":"2018","unstructured":"Veglia F, Perego M, Gabrilovich D (2018) Myeloid-derived suppressor cells coming of age. Nat Immunol 19(2):108\u2013119. https:\/\/doi.org\/10.1038\/s41590-017-0022-x","journal-title":"Nat Immunol"},{"key":"12017_CR87","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","volume":"29","author":"MD Vesely","year":"2011","unstructured":"Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ (2011) Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29:235\u2013271. https:\/\/doi.org\/10.1146\/annurev-immunol-031210-101324","journal-title":"Annu Rev Immunol"},{"issue":"6013","key":"12017_CR88","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.1198687","volume":"331","author":"E Vivier","year":"2011","unstructured":"Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Ugolini S (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331(6013):44\u201349. https:\/\/doi.org\/10.1126\/science.1198687","journal-title":"Science"},{"issue":"7755","key":"12017_CR89","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","volume":"569","author":"W Wang","year":"2019","unstructured":"Wang W, Green M, Choi JE, Gij\u00f3n M, Kennedy PD, Johnson JK, Stockwell BR (2019) CD8\u2009+\u2009T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 569(7755):270\u2013274. https:\/\/doi.org\/10.1038\/s41586-019-1170-y","journal-title":"Nature"},{"issue":"11","key":"12017_CR90","doi-asserted-by":"publisher","first-page":"5951","DOI":"10.1172\/JCI130445","volume":"130","author":"L Wang","year":"2020","unstructured":"Wang L, Yang L, Wang C, Zhao W, Ju Z, Zhang W, Peng G (2020) Inhibition of the ATM\/Chk2 axis promotes cGAS\/STING signaling in ARID1A-deficient tumors. J Clin Investig 130(11):5951\u20135966. https:\/\/doi.org\/10.1172\/JCI130445","journal-title":"J Clin Investig"},{"issue":"8","key":"12017_CR91","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M (2015) Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15(8):486\u2013499. https:\/\/doi.org\/10.1038\/nri3862","journal-title":"Nat Rev Immunol"},{"key":"12017_CR92","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/s41419-022-05341-3","volume":"13","author":"B Wiernicki","year":"2022","unstructured":"Wiernicki B, Dubois H, Tyurina YY, Hassannia B, Bayir H, Kagan VE, Vandenabeele P (2022) Excessive phospholipid peroxidation distinguishes ferroptosis from other cell death modes including pyroptosis. Cell Death Dis 13:922. https:\/\/doi.org\/10.1038\/s41419-022-05341-3","journal-title":"Cell Death Dis"},{"issue":"9","key":"12017_CR93","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Ribas A (2016) Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375(9):819\u2013829. https:\/\/doi.org\/10.1056\/NEJMoa1604958","journal-title":"N Engl J Med"},{"key":"12017_CR94","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41419-019-1509-6","volume":"10","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Yu Z, Ma R, Zhang Y, Zhao L, Yan Y, Zhang Y (2019) lncRNA-Xist\/miR-34a axis modulates the chemoresistance of breast cancer cells to doxorubicin by regulating the Wnt\/\u03b2-catenin signaling pathway. Cell Death Dis 10:280. https:\/\/doi.org\/10.1038\/s41419-019-1509-6","journal-title":"Cell Death Dis"},{"issue":"6382","key":"12017_CR95","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1126\/science.aar6918","volume":"359","author":"L Zitvogel","year":"2018","unstructured":"Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF (2018) The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science 359(6382):1366\u20131370. https:\/\/doi.org\/10.1126\/science.aar6918","journal-title":"Science"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12017-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12017-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12017-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:32:22Z","timestamp":1779802342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12017-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12017"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12017-0","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"831"}}